THERMO FISHER SCIENTIFIC INC
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
TMO$718.20-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31,
| December 31, | December 31, | |
|---|---|---|
| (In millions except share and per share amounts) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $8,077 | $8,524 |
| Accounts receivable, less allowances of $193 and $189 | 8,221 | 8,115 |
| Inventories | 5,088 | 5,634 |
| Contract assets, net | 1,443 | 1,312 |
| Other current assets | 1,760 | 1,644 |
| Total current assets | 24,589 | 25,229 |
| Property, plant and equipment, net | 9,448 | 9,280 |
| Acquisition-related intangible assets, net | 16,670 | 17,442 |
| Other assets | 3,999 | 4,007 |
| Goodwill | 44,020 | 41,196 |
| Total assets | $98,726 | $97,154 |
| Liabilities, redeemable noncontrolling interest and equity | ||
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | $3,609 | $5,579 |
| Accounts payable | 2,872 | 3,381 |
| Accrued payroll and employee benefits | 1,596 | 2,095 |
| Contract liabilities | 2,689 | 2,601 |
| Other accrued expenses | 3,246 | 3,354 |
| Total current liabilities | 14,012 | 17,010 |
| Deferred income taxes | 1,922 | 2,849 |
| Other long-term liabilities | 4,642 | 4,238 |
| Long-term obligations | 31,308 | 28,909 |
| Commitments and contingencies (Note 12) | ||
| Redeemable noncontrolling interest | 118 | 116 |
| Equity: | ||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | ||
| Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued | 442 | 441 |
| Capital in excess of par value | 17,286 | 16,743 |
| Retained earnings | 47,364 | 41,910 |
| Treasury stock at cost, 55,541,290 and 50,157,275 shares | (15,133) | (12,017) |
| Accumulated other comprehensive income/(loss) | (3,224) | (3,099) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 46,735 | 43,978 |
| Noncontrolling interests | (11) | 54 |
| Total equity | 46,724 | 44,032 |
| Total liabilities, redeemable noncontrolling interest and equity | $98,726 | $97,154 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.